Imatinib Mesylate Tablet, Film Coated
Product Images NDC 0378-2245

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 0378-2245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib Structural Formula (Image 01)

FDA Label Image

Imatinib Tablets 100 mg Bottle Label (Image 02)

Imatinib Tablets 100 mg Bottle Label (Image 02)
This is a prescription information for Imatinib Mesylate tablets. It contains the National Drug Code, precautions to avoid children reach, protection advice against moisture and the manufacturer's details. Made in Puerto Rico, it is distributed by Mylan Pharmaceuticals Inc. with a pack of 90 tablets.*
FDA Label Image

Imatinib Tablets 400 mg Bottle Label (Image 03)

Imatinib Tablets 400 mg Bottle Label (Image 03)
This is a medication description. The medication is a 375.2246.93 Dispense with light-resistant tablets used to treat conditions like Sydost and Mesylate. The tablets should be stored at room temperature and protected from moisture. This medication is available by prescription only and comes in a pack of 30 tablets. Additional information can be found on the Mylan website.*
FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Image 04)

Figure 1: Progression Free Survival (itt Principle) (Image 04)
This appears to be a statistical analysis related to medical research. The table provides information about patients with a certain condition and their progression or lack of progression during a certain period of time. The "Hazard Ratio" and "Log-rank Test" values suggest that there is a statistically significant difference between the two groups of patients mentioned in the table. Overall, it is not clear what specific condition is being analyzed or what the purpose of the research is.*
FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Image 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.